{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T16:44:48Z","timestamp":1790700288480,"version":"4.1.0"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2002,6,14]],"date-time":"2002-06-14T00:00:00Z","timestamp":1024012800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2002,6,14]],"date-time":"2002-06-14T00:00:00Z","timestamp":1024012800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Gene Ther"],"published-print":{"date-parts":[[2002,7,1]]},"DOI":"10.1038\/sj.cgt.7700472","type":"journal-article","created":{"date-parts":[[2002,9,3]],"date-time":"2002-09-03T18:44:09Z","timestamp":1031078649000},"page":"553-566","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":149,"title":["A phase I\/II trial of rAd\/p53 (SCH 58500) gene replacement in recurrent ovarian cancer"],"prefix":"10.1038","volume":"9","author":[{"given":"Richard E","family":"Buller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingo B","family":"Runnebaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth Y","family":"Karlan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo Ann","family":"Horowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Shahin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Buekers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stan","family":"Petrauskas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rolf","family":"Kreienberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis","family":"Slamon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Pegram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2002,6,14]]},"reference":[{"key":"BF7700472_CR1","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3322\/canjclin.51.1.15","volume":"51","author":"RT Greenlee","year":"2001","unstructured":"Greenlee RT, Hill-Harman MB, Murray T, Thun M . Cancer statistics, 2001 Ca-Cancer J Clin 2001 51: 15\u201336","journal-title":"Ca-Cancer J Clin"},{"key":"BF7700472_CR2","unstructured":"International Federation of Gynecology and Obstetrics Annual Report on the Results of Treatment in Gynecological Cancer Stockholm: FIGO 1994 24"},{"key":"BF7700472_CR3","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1006\/gyno.1995.1134","volume":"57","author":"J Geisler","year":"1995","unstructured":"Geisler J, Geisler H . Brain metastases in epithelial ovarian carcinoma Gynecol Oncol 1995 57: 246\u2013249","journal-title":"Gynecol Oncol"},{"key":"BF7700472_CR4","first-page":"2485","volume":"5","author":"AK Sood","year":"1999","unstructured":"Sood AK, Sorosky J, Dolan M et al. Distant metastases in ovarian cancer: why do they occur? Clin Cancer Res 1999 5: 2485\u20132490","journal-title":"Clin Cancer Res"},{"key":"BF7700472_CR5","first-page":"101","volume":"42","author":"CT Griffiths","year":"1975","unstructured":"Griffiths CT . Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma Natl Cancer Inst Monogr 1975 42: 101\u2013104","journal-title":"Natl Cancer Inst Monogr"},{"key":"BF7700472_CR6","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1016\/S0002-9378(94)70090-7","volume":"170","author":"WJ Hoskins","year":"1994","unstructured":"Hoskins WJ, McGuire WP, Brady MF et al. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma Am J of Obstet Gynecol 1994 170: 974\u2013979","journal-title":"Am J of Obstet Gynecol"},{"key":"BF7700472_CR7","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/0090-8258(88)90262-4","volume":"31","author":"KC Podratz","year":"1988","unstructured":"Podratz KC, Schray MF, Wieand HS et al. Evaluation of treatment and survival after positive second-look laparotomy Gynecol Oncol 1988 31: 9\u201324","journal-title":"Gynecol Oncol"},{"key":"BF7700472_CR8","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/0090-8258(89)90175-3","volume":"34","author":"WJ Hoskins","year":"1989","unstructured":"Hoskins WJ, Rubin SC, Dulaney E et al. Influence of secondary cytoreduction at the time of second-look laparotomy on the survival of patients with epithelial ovarian carcinoma Gynecol Oncol 1989 34: 365\u2013372","journal-title":"Gynecol Oncol"},{"key":"BF7700472_CR9","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/351453a0","volume":"351","author":"AJ Levine","year":"1991","unstructured":"Levine AJ, Momand J, Finlay CA . The p53 tumour suppressor gene Nature 1991 351: 453\u2013456","journal-title":"Nature"},{"key":"BF7700472_CR10","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1093\/jnci\/88.20.1442","volume":"88","author":"CC Harris","year":"1996","unstructured":"Harris CC . Structure and function of the p53 tumor suppressor gene: clues for rational cancer therapeutic strategies J Natl Cancer Inst 1996 88: 1442\u20131455","journal-title":"J Natl Cancer Inst"},{"key":"BF7700472_CR11","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/BF00665797","volume":"14","author":"JM Lee","year":"1995","unstructured":"Lee JM, Bernstein A . Apoptosis, cancer and the p53 tumour suppressor gene Cancer Metastasis Rev 1995 14: 149\u2013161","journal-title":"Cancer Metastasis Rev"},{"key":"BF7700472_CR12","first-page":"892","volume":"56","author":"DS Hawkins","year":"1996","unstructured":"Hawkins DS, Demers GW, Galloway DA . Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents Cancer Res 1996 56: 892\u2013898","journal-title":"Cancer Res"},{"key":"BF7700472_CR13","doi-asserted-by":"publisher","first-page":"3158","DOI":"10.1200\/JCO.1998.16.9.3158","volume":"16","author":"DG Kirsch","year":"1998","unstructured":"Kirsch DG, Kastan MB . Tumor-suppressor p53: implications for tumor development and prognosis J Clin Oncol 1998 16: 3158\u20133168 (Review)","journal-title":"J Clin Oncol"},{"key":"BF7700472_CR14","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/sj.onc.1202314","volume":"18","author":"G Blandino","year":"1999","unstructured":"Blandino G, Levine AJ, Oren M . Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy Oncogene 1999 18: 477\u2013485","journal-title":"Oncogene"},{"key":"BF7700472_CR15","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1097\/00004347-199901000-00005","volume":"18","author":"W Wen","year":"1999","unstructured":"Wen W, Reles A, Runnebaum IB et al. P53 mutations and expression in ovarian cancers: correlation with overall survival Int J Gynecol Pathol 1999 18: 29\u201341","journal-title":"Int J Gynecol Pathol"},{"key":"BF7700472_CR16","first-page":"117","volume":"13","author":"JS Skilling","year":"1996","unstructured":"Skilling JS, Sood AK, Niemann T et al. An abundance of p53 null mutations in ovarian carcinoma Oncogene 1996 13: 117\u2013123","journal-title":"Oncogene"},{"key":"BF7700472_CR17","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1002\/1097-0142(20001101)89:9<2006::AID-CNCR18>3.3.CO;2-Z","volume":"89","author":"M Shahin","year":"2000","unstructured":"Shahin M, Sood AK, Hughes JH et al. The prognostic significance of p53 tumor suppressor gene alterations in ovarian cancer Cancer 2000 89: 2006\u20132017","journal-title":"Cancer"},{"key":"BF7700472_CR18","first-page":"1","volume":"12","author":"RL Dedrick","year":"1986","unstructured":"Dedrick RL . Theoretical and experimental bases of intraperitoneal chemotherapy Semin Oncol 1986 12: 1\u20136","journal-title":"Semin Oncol"},{"key":"BF7700472_CR19","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.1056\/NEJM199612263352603","volume":"335","author":"DS Alberts","year":"1996","unstructured":"Alberts DS, Liu PY, Hannigan EV et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer N Engl J Med 1996 335: 1950\u20131955","journal-title":"N Engl J Med"},{"key":"BF7700472_CR20","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1093\/ajcp\/109.4.444","volume":"109","author":"J Gomez-Navarro","year":"1998","unstructured":"Gomez-Navarro J, Siegal GP, Alvarez RD et al. Gene therapy: ovarian carcinoma as the paradigm Am J Clin Pathol 1998 109: 444\u2013467","journal-title":"Am J Clin Pathol"},{"key":"BF7700472_CR21","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1097\/00001813-199911001-00008","volume":"10","author":"J Baselga","year":"1999","unstructured":"Baselga J . New horizons: gene therapy for cancer Anti-Cancer Drugs 1999 10: 39\u201342","journal-title":"Anti-Cancer Drugs"},{"key":"BF7700472_CR22","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1089\/hum.1998.9.5-681","volume":"9","author":"LL Nielsen","year":"1998","unstructured":"Nielsen LL, Gurnani M, Syed J et al. Recombinant E1-deleted adenovirus-mediated gene therapy for cancer: efficacy studies with p53 tumor suppressor gene and liver histology in mouse tumor xenograft models Hum Gene Ther 1998 9: 681\u2013694","journal-title":"Hum Gene Ther"},{"key":"BF7700472_CR23","first-page":"835","volume":"4","author":"LL Nielsen","year":"1998","unstructured":"Nielsen LL, Lipari P, Dell J et al. Adenovirus-mediated p53 gene therapy and paclitaxel have synergistic efficacy in models of human head and neck, ovarian, prostate, and breast cancer Clin Cancer Res 1998 4: 835\u2013846","journal-title":"Clin Cancer Res"},{"key":"BF7700472_CR24","first-page":"129","volume":"4","author":"LL Nielsen","year":"1997","unstructured":"Nielsen LL, Dell J, Maxwell E et al. Efficacy of p53 adenovirus-mediated gene therapy against human breast cancer xenografts Cancer Gene Ther 1997 4: 129\u2013138","journal-title":"Cancer Gene Ther"},{"key":"BF7700472_CR25","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1038\/sj.gt.3300508","volume":"4","author":"JL Bramson","year":"1997","unstructured":"Bramson JL, Hitt M, Gauldie J et al. Pre-existing immunity to adenovirus does not prevent tumor regression following intratumoral administration of a vector expressing IL-12 but inhibits virus dissemination Gene Ther 1997 4: 1069\u20131076","journal-title":"Gene Ther"},{"key":"BF7700472_CR26","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1006\/gyno.1998.5010","volume":"69","author":"VE von Gruenigen","year":"1998","unstructured":"von Gruenigen VE, Santoso JT, Coleman RL et al. In vivo studies of adenovirus-based p53 gene therapy for ovarian cancer Gynecol Oncol 1998 69: 197\u2013204","journal-title":"Gynecol Oncol"},{"key":"BF7700472_CR27","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1038\/sj.cgt.7700006","volume":"6","author":"J Kim","year":"1999","unstructured":"Kim J, Hwang ES, Kim JS et al. Intraperitoneal gene therapy with adenoviral-mediated p53 tumor suppressor gene for ovarian cancer model in nude mouse Cancer Gene Ther 1999 6: 172\u2013178","journal-title":"Cancer Gene Ther"},{"key":"BF7700472_CR28","first-page":"1649","volume":"4","author":"SC Anderson","year":"1998","unstructured":"Anderson SC, Johnson DE, Harris MP et al. P53 gene therapy in a rat model for hepatocellular carcinoma: intra-arterial delivery of a recombinant adenovirus Clin Cancer Res 1998 4: 1649\u20131659","journal-title":"Clin Cancer Res"},{"key":"BF7700472_CR29","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s002800050959","volume":"44","author":"M Gurnani","year":"1999","unstructured":"Gurnani M, Lipari P, Dell J et al. Adenovirus-mediated p53 gene therapy has greater efficacy when combined with chemotherapy against human head and neck, ovarian, prostate, and breast cancer Cancer Chemother Pharmacol 1999 44: 143\u2013151","journal-title":"Cancer Chemother Pharmacol"},{"key":"BF7700472_CR30","first-page":"2287","volume":"54","author":"T Fujiwara","year":"1994","unstructured":"Fujiwara T, Grimm EA, Mukhopadhyay T et al. Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene Cancer Res 1994 54: 2287\u20132291","journal-title":"Cancer Res"},{"key":"BF7700472_CR31","first-page":"5","volume":"1","author":"W-W Zhang","year":"1994","unstructured":"Zhang W-W, Fang X, Mazur W et al. High-efficiency gene transfer and high-level expression of wild-type p53 in human lung cancer cells mediated by recombinant adenovirus Cancer Gene Ther 1994 1: 5\u201313","journal-title":"Cancer Gene Ther"},{"key":"BF7700472_CR32","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1038\/nm0996-985","volume":"2","author":"JA Roth","year":"1996","unstructured":"Roth JA, Nguyen D, Lawrence DD et al. Retrovirus-mediated wild-type gene transfer to tumors of patients with lung cancer Nat Med 1996 2: 985\u2013991","journal-title":"Nat Med"},{"key":"BF7700472_CR33","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1200\/JCO.2000.18.3.609","volume":"18","author":"J Nemunaitis","year":"2000","unstructured":"Nemunaitis J, Swisher SG, Timmons T et al. Adenovirus-mediated p53 gene transfer in sequence with cisplatin to tumors of patients with non-small-cell lung cancer J Clin Oncol 2000 18: 609\u2013622","journal-title":"J Clin Oncol"},{"key":"BF7700472_CR34","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1200\/JCO.1998.16.6.2221","volume":"16","author":"GL Clayman","year":"1998","unstructured":"Clayman GL, El-Naggar AK, Lippman SM et al. Adenovirus-mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma J Clin Oncol 1998 16: 2221\u20132232","journal-title":"J Clin Oncol"},{"key":"BF7700472_CR35","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1093\/jnci\/91.9.763","volume":"91","author":"SG Swisher","year":"1999","unstructured":"Swisher SG, Roth JA, Nemunaitis J et al. Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer J Natl Cancer Inst 1999 91: 763\u2013771","journal-title":"J Natl Cancer Inst"},{"key":"BF7700472_CR36","first-page":"245","volume":"3","author":"JC Cusack","year":"1996","unstructured":"Cusack JC, Spitz FR, Nguyen D et al. High levels of gene transduction in human lung tumors following intralesional injection of recombinant adenovirus Cancer Gene Ther 1996 3: 245\u2013249","journal-title":"Cancer Gene Ther"},{"key":"BF7700472_CR37","first-page":"52","volume":"5","author":"LL Nielsen","year":"1998","unstructured":"Nielsen LL, Maneval DC . P53 tumor suppressor gene therapy for cancer Cancer Gene Ther 1998 5: 52\u201363","journal-title":"Cancer Gene Ther"},{"key":"BF7700472_CR38","first-page":"452","volume":"72","author":"RE Buller","year":"1999","unstructured":"Buller RE, Pegram M, Runnebaum I et al. A phase I\/II trial of recombinant adenoviral human p53 (SCH 58500) intraperitoneal (IP) gene therapy in recurrent ovarian cancer Gynecol Oncol 1999 72: 452\u2013453","journal-title":"Gynecol Oncol"},{"key":"BF7700472_CR39","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1089\/hum.1994.5.9-1079","volume":"5","author":"KN Wills","year":"1994","unstructured":"Wills KN, Maneval DC, Menzel P et al. Development and characterization of recombinant adenoviruses encoding human p53 for gene therapy of cancer Hum Gen Ther 1994 5: 1079\u20131088","journal-title":"Hum Gen Ther"},{"key":"BF7700472_CR40","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1159\/000180580","volume":"16","author":"DW Cockcroft","year":"1976","unstructured":"Cockcroft DW, Gault MH . Prediction of creatinine clearance from serum creatinine Nephron 1976 16: 31\u201341","journal-title":"Nephron"},{"key":"BF7700472_CR41","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1200\/JCO.1996.14.5.1545","volume":"14","author":"GJ Rustin","year":"1996","unstructured":"Rustin GJ, Nelstrop AE, McClean P et al. Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125 J Clin Oncol 1996 14: 1545\u20131551","journal-title":"J Clin Oncol"},{"key":"BF7700472_CR42","doi-asserted-by":"publisher","first-page":"S21","DOI":"10.1023\/A:1008351216605","volume":"10","author":"GJ Rustin","year":"1999","unstructured":"Rustin GJ, Nelstrop AE, Bentzen SM et al. Use of tumour markers in monitoring the course of ovarian cancer Ann Oncol 1999 10: S21\u2013S27","journal-title":"Ann Oncol"},{"key":"BF7700472_CR43","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1002\/(SICI)1097-0320(19981101)33:3<290::AID-CYTO2>3.0.CO;2-L","volume":"33","author":"ML Musco","year":"1998","unstructured":"Musco ML, Cui S, Small D et al. A comparison of flow cytometry and laser scanning cytometry for the intracellular evaluation of adenoviral infectivity and p53 protein expression in gene therapy Cytometry 1998 33: 290\u2013296","journal-title":"Cytometry"},{"key":"BF7700472_CR44","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1006\/gyno.1999.5565","volume":"75","author":"JK Wolf","year":"1999","unstructured":"Wolf JK, Mills G, Bazzet L et al. Adenovirus-mediated p53 growth inhibition of ovarian cancer cells is independent of endogenous p53 status Gynecol Oncol 1999 75: 261\u2013266","journal-title":"Gynecol Oncol"},{"key":"BF7700472_CR45","first-page":"1617","volume":"12","author":"K Mujoo","year":"1996","unstructured":"Mujoo K, Maneval DC, Anderson SC et al. Adenoviral-mediated p53 tumor suppressor gene therapy of human ovarian carcinoma Oncogene 1996 12: 1617\u20131623","journal-title":"Oncogene"},{"key":"BF7700472_CR46","first-page":"3117","volume":"55","author":"T-J Liu","year":"1995","unstructured":"Liu T-J, el-Naggar AK, McDonnell TJ et al. Apoptosis induction mediated by wild-type p53 adenoviral gene transfer in squamous cell carcinoma of the head and neck Cancer Res 1995 55: 3117\u20133122","journal-title":"Cancer Res"},{"key":"BF7700472_CR47","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1126\/science.2274789","volume":"250","author":"P-L Chen","year":"1990","unstructured":"Chen P-L, Chen Y, Bookstein R et al. Genetic mechanisms of tumor suppression by the human p53 gene Science 1990 250: 1576\u20131580","journal-title":"Science"},{"key":"BF7700472_CR48","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1097\/00001622-199401000-00014","volume":"6","author":"T Fujiwara","year":"1994","unstructured":"Fujiwara T, Grimm EA, Roth JA . Gene therapeutics and gene therapy for cancer Curr Opin Oncol 1994 6: 96\u2013105","journal-title":"Curr Opin Oncol"},{"key":"BF7700472_CR49","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1001\/jama.1955.02960350004002","volume":"159","author":"AS Weisberger","year":"1955","unstructured":"Weisberger AS, Levine B, Storaasli JP . Use of nitrogen mustard in treatment of serous effusions of neoplastic origin J Am Med Assoc 1955 159: 1704\u20131707","journal-title":"J Am Med Assoc"},{"key":"BF7700472_CR50","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1006\/gyno.1999.5532","volume":"75","author":"JS Berek","year":"1999","unstructured":"Berek JS, Markman M, Stonebraker B et al. Intraperitoneal interferon-\u03b1 in residual ovarian carcinoma: a phase II gynecologic oncology group study Gynecol Oncol 1999 75: 10\u201314","journal-title":"Gynecol Oncol"},{"key":"BF7700472_CR51","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1006\/gyno.1999.5613","volume":"75","author":"RJ Morgan Jr","year":"1999","unstructured":"Morgan RJ Jr, Braly P, Cecchi G et al. Phase II trial of intraperitoneal cisplatin with intravenous doxorubicin and cyclophosphamide in previously untreated patients with advanced ovarian cancer \u2014 long-term follow-up Gynecol Oncol 1999 75: 419\u2013426","journal-title":"Gynecol Oncol"},{"key":"BF7700472_CR52","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1006\/gyno.1998.4973","volume":"69","author":"RR Barakat","year":"1998","unstructured":"Barakat RR, Almadrones L, Venkatraman ES et al. A phase II trial of intraperitoneal cisplatin and etoposide as consolidation therapy in patients with stage II\u2013IV epithelial ovarian cancer following negative surgical assessment Gynecol Oncol 1998 69: 17\u201322","journal-title":"Gynecol Oncol"},{"key":"BF7700472_CR53","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1006\/gyno.1996.0163","volume":"61","author":"FM Muggia","year":"1996","unstructured":"Muggia FM, Liu PY, Alberts DS et al. Intraperitoneal mitoxantrone or floxuridine: effects on time-to-failure and survival in patients with minimal residual ovarian cancer after second-look laparotomy \u2014 a randomized phase II study by the Southwest Oncology Group Gynecol Oncol 1996 61: 395\u2013402","journal-title":"Gynecol Oncol"},{"key":"BF7700472_CR54","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1200\/JCO.1992.10.9.1479","volume":"10","author":"M Markman","year":"1992","unstructured":"Markman M, Reichman B, Hakes T et al. Impact on survival of surgically defined favorable responses to salvage intraperitoneal chemotherapy in small-volume residual ovarian cancer J Clin Oncol 1992 10: 1479\u20131484","journal-title":"J Clin Oncol"},{"key":"BF7700472_CR55","doi-asserted-by":"publisher","first-page":"2620","DOI":"10.1200\/JCO.1998.16.8.2620","volume":"16","author":"M Markman","year":"1998","unstructured":"Markman M, Brady MF, Spirtos NM et al. Phase II trial of intraperitoneal paclitaxel in carcinoma of the ovary, tube, and peritoneum: a Gynecologic Oncology Group Study J Clin Oncol 1998 16: 2620\u20132624","journal-title":"J Clin Oncol"},{"key":"BF7700472_CR56","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1089\/hum.1996.7.9-1161","volume":"7","author":"CJ Link Jr","year":"1996","unstructured":"Link CJ Jr, Moorman D, Seregina T et al. A phase I trial of in vivo gene therapy with the herpes simplex thymidine kinase\/ganciclovir system for the treatment of refractory or recurrent ovarian cancer Hum Gene Ther 1996 7: 1161\u20131179","journal-title":"Hum Gene Ther"},{"key":"BF7700472_CR57","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1089\/hum.1997.8.5-597","volume":"8","author":"RD Alvarez","year":"1997","unstructured":"Alvarez RD, Curiel DT . A phase I study of recombinant adenovirus vector\u2013mediated intraperitoneal delivery of herpes simplex virus thymidine kinase (HSV-TK) gene and intravenous ganciclovir for previously treated ovarian and extraovarian cancer patients Hum Gene Ther 1997 8: 597\u2013613","journal-title":"Hum Gene Ther"},{"key":"BF7700472_CR58","first-page":"2163","volume":"19","author":"A Hasenburg","year":"1999","unstructured":"Hasenburg A, Tong XW, Rojas-Martinez A et al. Thymidine kinase (TK) gene therapy of solid tumors: valacyclovir facilitates outpatient treatment Anticancer Res 1999 19: 2163\u20132165","journal-title":"Anticancer Res"},{"key":"BF7700472_CR59","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1089\/hum.1998.9.12-1775","volume":"9","author":"GN Hortobagyi","year":"1998","unstructured":"Hortobagyi GN, Hung MC, Lopez-Berestein G . A phase I multicenter study of E1A gene therapy for patients with metastatic breast cancer and epithelial ovarian cancer that overexpresses HER-2\/neu or epithelial ovarian cancer Hum Gene Ther 1998 9: 1775\u20131798","journal-title":"Hum Gene Ther"},{"key":"BF7700472_CR60","first-page":"1959","volume":"3","author":"DL Tait","year":"1997","unstructured":"Tait DL, Obermiller PS, Redlin-Frazier S et al. A phase I trial of retroviral BRCA1sv gene therapy in ovarian cancer Clin Cancer Res 1997 3: 1959\u20131968","journal-title":"Clin Cancer Res"},{"key":"BF7700472_CR61","first-page":"1708","volume":"5","author":"DL Tait","year":"1999","unstructured":"Tait DL, Obermiller PS, Hatmaker AR et al. Ovarian cancer BRCA1 gene therapy: phase I and II trial differences in immune response and vector stability Clin Cancer Res 1999 5: 1708\u20131714","journal-title":"Clin Cancer Res"},{"key":"BF7700472_CR62","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1016\/S0002-9440(10)65506-X","volume":"155","author":"MJ Grace","year":"1999","unstructured":"Grace MJ, Xie L, Musco ML et al. The use of laser scanning cytometry to assess depth of penetration of adenovirus p53 gene therapy in human xenograft biopsies Am J Pathol 1999 155: 1869\u20131878","journal-title":"Am J Pathol"},{"key":"BF7700472_CR63","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/S1054-3589(08)60140-4","volume":"40","author":"M Hitt","year":"1997","unstructured":"Hitt M, Addison CL, Graham FL . Human adenovirus vectors for gene transfer into mammalian cells Adv Pharmacol 1997 40: 137\u2013206","journal-title":"Adv Pharmacol"},{"key":"BF7700472_CR64","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1126\/science.275.5304.1320","volume":"275","author":"JM Bergelson","year":"1997","unstructured":"Bergelson JM, Cunningham JA, Droguett G et al. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5 Science 1997 275: 1320\u20131323","journal-title":"Science"},{"key":"BF7700472_CR65","first-page":"325","volume":"59","author":"L Yingming","year":"1999","unstructured":"Yingming L, Pong R-C, Bergelson JM et al. Loss of adenoviral receptor expression in human bladder cancer cells: a potential impact on the efficacy of gene therapy Cancer Res 1999 59: 325\u2013330","journal-title":"Cancer Res"},{"key":"BF7700472_CR66","first-page":"452","volume":"72","author":"M Pegram","year":"1999","unstructured":"Pegram M, Tseng Y, Baldwin RL et al. Expression of coxsackie and adenovirus receptor (CAR) correlates with efficiency of adenovirus transduction of human ovarian carcinoma cells Gynecol Oncol 1999 72: 452","journal-title":"Gynecol Oncol"},{"key":"BF7700472_CR67","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/0002-9378(91)90093-7","volume":"165","author":"RE Buller","year":"1991","unstructured":"Buller RE, Berman ML, Bloss JD et al. CA 125 regression: a model for epithelial ovarian cancer response Am J Obstet Gynecol 1991 165: 360\u2013367","journal-title":"Am J Obstet Gynecol"},{"key":"BF7700472_CR68","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1016\/S0002-9378(96)70667-1","volume":"174","author":"RE Buller","year":"1996","unstructured":"Buller RE, Vasilev S, DiSaia PJ . CA125 kinetics: a cost effective clinical tool to evaluate clinical trial outcomes in the 1990s Am J Obstet Gynecol 1996 174: 1241\u20131254","journal-title":"Am J Obstet Gynecol"},{"key":"BF7700472_CR69","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/0090-8258(88)90244-2","volume":"30","author":"MEL van der Burg","year":"1988","unstructured":"van der Burg MEL, Lammes FB, van Putten WLJ et al. Ovarian cancer: the prognostic value of the serum half-life of CA125 during induction chemotherapy Gynecol Oncol 1988 30: 307\u2013312","journal-title":"Gynecol Oncol"},{"key":"BF7700472_CR70","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1200\/JCO.1989.7.11.1667","volume":"7","author":"GJS Rustin","year":"1989","unstructured":"Rustin GJS, Gennings JN, Nelstrop AE et al. Use of CA-125 to predict survival of patients with ovarian carcinoma J Clin Oncol 1989 7: 1667\u20131671","journal-title":"J Clin Oncol"},{"key":"BF7700472_CR71","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1016\/S0959-8049(05)80203-5","volume":"29A","author":"CA Yedema","year":"1993","unstructured":"Yedema CA, Kenemans P, Thomas CM et al. CA125 serum levels in the early post-operative period do not reflect tumour reduction obtained by cytoreductive surgery Eur J Cancer 1993 29A: 966\u2013971","journal-title":"Eur J Cancer"},{"key":"BF7700472_CR72","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1111\/j.1471-0528.1990.tb02450.x","volume":"97","author":"AG Van Der Zee","year":"1990","unstructured":"Van Der Zee AG, Duk JM, Aalders JG et al. The effect of abdominal surgery on the serum concentration of the tumour-associated antigen CA 125 Br J Obstet Gynaecol 1990 97: 934\u2013938","journal-title":"Br J Obstet Gynaecol"},{"key":"BF7700472_CR73","first-page":"407","volume":"168","author":"RW Talbot","year":"1989","unstructured":"Talbot RW, Jacobsen DJ, Nagorney DM et al. Temporary elevation of CA 125 after abdominal surgical treatment for benign disease and cancer Surg Gynecol Obstet 1989 168: 407\u2013412","journal-title":"Surg Gynecol Obstet"},{"key":"BF7700472_CR74","first-page":"3129","volume":"17","author":"AG Zeimet","year":"1997","unstructured":"Zeimet AG, Offner FA, Marth C et al. Modulation of CA-125 release by inflammatory cytokines in human peritoneal mesothelial and ovarian cancer cells Anticancer Res 1997 17: 3129\u20133131","journal-title":"Anticancer Res"},{"key":"BF7700472_CR75","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1200\/JCO.1987.5.10.1607","volume":"5","author":"SB Howell","year":"1987","unstructured":"Howell SB, Zimm S, Markman M et al. Long-term survival of advanced refractory ovarian carcinoma patients with small-volume disease treated with intraperitoneal chemotherapy J Clin Oncol 1987 5: 1607\u20131612","journal-title":"J Clin Oncol"}],"container-title":["Cancer Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/7700472.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/7700472","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/7700472.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,22]],"date-time":"2022-03-22T13:21:28Z","timestamp":1647955288000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/7700472"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,6,14]]},"references-count":75,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2002,7,1]]}},"alternative-id":["BF7700472"],"URL":"https:\/\/doi.org\/10.1038\/sj.cgt.7700472","relation":{},"ISSN":["0929-1903","1476-5500"],"issn-type":[{"value":"0929-1903","type":"print"},{"value":"1476-5500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,6,14]]},"assertion":[{"value":"4 April 2002","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2002","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}